HORSHAM, Pa., July 30, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for induction and consolidation in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (ASCT).1 Patients will have the opportunity to receive this DARZALEX FASPRO®-based quadruplet therapy at initial diagnosis, providing them with a new treatment that may significantly improve outcomes.
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from...
100% of patients enrolled achieved a partial response or betterMilder and less frequent drug-related adverse events were observed compared to those associated with Revlimid®No grade 3 or greater...
Enforcement Report - Week of June 5, 2024
Zydus receives final approval from USFDA for Dexamethasone Tablets
ProMed Pharma Acquires SpineThera Manufacturing Capabilities and an Option to License Intellectual Property
Zydus Pharma`s Generic Dexamethasone Receives Approval in the U.S.
Zydus Pharma`s Generic Dexamethasone Receives Approval in the U.S.
GSK details combo data that could bring Blenrep back to life